MedTrace Logo

Adjunctive, Low-dose tPA in Primary PCI for STEMI

NCT03335839 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2026-05-11

No results posted yet for this study

Summary

STRIVE will evaluate the use of adjunctive, low-dose intracoronary tissue plasminogen activator during primary percutaneous coronary intervention (PCI) for patients with ST elevation myocardial infarction (STEMI) in reducing the incidence of post-procedural myocardial blush (MBG) grade 0/1 or distal embolization.

Conditions

Interventions

DRUG

tissue plasminogen activator

Recombinant tPA is a fibrin-specific 2nd generation plasminogen activator and thrombolytic drug.

OTHER

Saline

Placebo

Sponsors & Collaborators

  • Heart and Stroke Foundation of Canada

    collaborator OTHER

  • Population Health Research Institute

    lead OTHER

Principal Investigators

  • Shamir Mehta, MD · McMaster University, Hamilton Health Sciences, Population Health Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-01
Primary Completion
2024-09-17
Completion
2025-02-12

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03335839 on ClinicalTrials.gov